Brief: Prophase Labs Announces Licensing Of New Investigational Cancer Compounds

Prophase Labs

21/07/2022 14:13

July 21 (Reuters) - 
    * PROPHASE LABS ANNOUNCES LICENSING OF NEW INVESTIGATIONAL CANCER COMPOUNDS
    * PROPHASE LABS - PROPHASE BIOPHARMA HAS EXECUTED LICENSE AGREEMENT WITH
GLOBAL
BIOLIFE, INC FOR LINEBACKER PORTFOLIO (LB-1 AND LB-2)
    * PROPHASE LABS - ANNOUNCED CONTINUED YEAR-OVER-YEAR QUARTERLY GROWTH IN
REVENUES
AND EARNINGS FOR Q2 2022, PROJECTED YEAR-OVER-YEAR GROWTH IN Q3 2022
    * PROPHASE LABS INC - PROPHASE PLANS TO WORK WITH DARYL THOMPSON AND GRDG TO
CONTINUE DEVELOPMENT OF LINEBACKER PORTFOLIO
    * PROPHASE LABS INC - ANNOUNCES SIGNIFICANT PROGRESS BEING MADE IN GENOMICS
BUSINESS

Source text for Eikon:  ID:nGNX71RJdk 

 ((Reuters.Briefs@thomsonreuters.com;))